– El objetivo es promover la profesionalización y actualización del...Leer más
AstraZeneca’s two-dose adenovirus-vectored vaccine (AZD1222) had 79% efficacy in preventing symptomatic COVID-19 among adults in the U.S., Peru, and Chile, according to interim phase 3 trial results. The company expects to request emergency use authorization in the U.S. in the coming weeks.
Researchers randomized over 32,000 adults at increased risk for COVID-19 to receive two doses of the vaccine or placebo, 4 weeks apart. Of these, 141 people developed symptomatic COVID-19. In addition to preventing symptomatic illness, the vaccine had 100% efficacy for preventing severe or critical disease and hospitalization.
For adults 65 and older, the efficacy against symptomatic COVID-19 was 80%.
Of the 22,000 people who received at least one dose of the vaccine, none developed cerebral venous sinus thrombosis (CVST), higher rates of which have been observed in vaccine recipients in Europe. There was also no increased risk for thrombosis in general.
Créditos: Comité científico Covid